Can a patient receiving dialysis safely take gabapentin?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Patients on Dialysis Take Gabapentin?

Yes, patients on dialysis can take gabapentin, but the dose must be substantially reduced to prevent serious adverse effects including altered mental status, falls, and fractures. Gabapentin is removed by hemodialysis and requires careful dose adjustment based on residual renal function and dialysis schedule 1.

Dosing Requirements for Dialysis Patients

Gabapentin is primarily renally excreted and accumulates dramatically in dialysis patients. The elimination half-life increases from 5-7 hours in normal renal function to approximately 132 hours in anuric patients, but drops to 3.8 hours during active hemodialysis 1. This creates a critical need for dose reduction.

For hemodialysis patients:

  • Maintenance doses must be reduced to 100-300 mg daily (compared to standard doses of 900-3600 mg/day in patients with normal renal function)
  • Supplemental doses of 200-300 mg should be given after each dialysis session to replace drug removed during dialysis 1
  • Even doses as low as 100-300 mg daily are associated with increased adverse events 2

For peritoneal dialysis patients:

  • Similar dose reductions are required, though peritoneal dialysis removes less gabapentin than hemodialysis
  • A case report documented serious toxicity (fall with hip fracture) in an 89-year-old peritoneal dialysis patient prescribed 300 mg three times daily—a dose far too high for this population 3

Critical Safety Concerns

The evidence consistently demonstrates that gabapentin use in dialysis patients carries substantial risks:

Altered mental status: Gabapentin increases the hazard of altered mental status by 31-50%, even at lower doses (>0-100 mg daily), with risk increasing to 50% at doses >300 mg daily 2. This risk is amplified in frail patients, with those having severe frailty experiencing a 3.22-fold increased hazard of altered mental status when taking gabapentin 4.

Falls and fractures: The medication increases fall risk by 26-55% depending on dose, with fracture risk elevated by 38% at higher doses 2. Recent data confirms a 55% increased hazard of falls even with appropriate dosing 4. The case in the guideline literature illustrates this dramatically—a patient on peritoneal dialysis fell and sustained a hip fracture requiring replacement after being prescribed inappropriately high gabapentin doses 3.

Coprescribing risks: When gabapentin is combined with other psychoactive medications (opioids, sedatives, benzodiazepines), the risks multiply substantially. Coprescribing increases the hazard of altered mental status by 66% and falls by 55% 4. This is particularly concerning as 68% of dialysis patients taking gabapentin also have prescriptions for opioids or other psychoactive medications 2.

Common Prescribing Errors

Inappropriately high doses are frequently prescribed to dialysis patients. Studies show that 34-48.8% of dialysis patients with creatinine clearance <60 mL/min receive gabapentin doses exceeding manufacturer recommendations 5. The case report in the American Journal of Kidney Diseases specifically highlights how gabapentin 300 mg three times daily (900 mg/day total) was inappropriately prescribed to a peritoneal dialysis patient, leading to fall and fracture 3.

Clinical Algorithm for Gabapentin Use in Dialysis

  1. Verify indication: Ensure gabapentin is necessary for neuropathic pain, uremic pruritus, or restless legs syndrome. Consider alternatives first.

  2. Start with minimal dosing:

    • Hemodialysis: 100 mg daily, with 200-300 mg supplemental dose after each dialysis session
    • Peritoneal dialysis: 100-200 mg daily maximum
  3. Monitor closely for:

    • Sedation, dizziness, confusion (check at each dialysis session)
    • Falls or near-falls (question patient and family directly)
    • Changes in mental status
  4. Review all concomitant medications:

    • Identify and minimize other psychoactive medications (opioids, benzodiazepines, sedatives)
    • If coprescribing is unavoidable, use the absolute lowest effective doses and increase monitoring frequency
  5. Consider drug level monitoring: Though not routinely available, therapeutic drug monitoring can prevent toxicity, particularly when symptoms are ambiguous 6.

  6. Reassess frailty status: Patients with higher frailty scores face disproportionately higher risks and may not be appropriate candidates for gabapentin 4.

Key Pitfalls to Avoid

  • Never use standard dosing: The 300 mg three times daily commonly prescribed to patients with normal renal function is dangerously excessive for dialysis patients
  • Don't assume symptoms are unrelated: Confusion, falls, or sedation in a dialysis patient on gabapentin should prompt immediate dose reduction or discontinuation, not extensive neurological workup 6
  • Don't forget post-dialysis supplementation: Hemodialysis removes significant gabapentin; failure to supplement leads to inadequate symptom control
  • Avoid polypharmacy: Each additional psychoactive medication compounds the risk exponentially 4

The FDA label explicitly states that gabapentin can be removed by hemodialysis and that coma has been reported in patients with chronic renal failure treated with gabapentin 1. While gabapentin can be used safely in dialysis patients, it requires meticulous dose adjustment, vigilant monitoring, and careful consideration of the risk-benefit ratio in each individual case.

References

Research

Gabapentin and Pregabalin Use and Association with Adverse Outcomes among Hemodialysis Patients.

Journal of the American Society of Nephrology : JASN, 2018

Research

Association of Coprescribing of Gabapentinoid and Other Psychoactive Medications With Altered Mental Status and Falls in Adults Receiving Dialysis.

American journal of kidney diseases : the official journal of the National Kidney Foundation, 2025

Research

Evaluation of Gabapentin and Pregabalin Use in Hospitalized Patients With Decreased Kidney Function.

The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians, 2024

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.